Global Bipolar Disorders and Treatment Market Information by Drugs (Chronic Bronchitis, Emphysema), by Treatment (Oxygen Therapy, Lung Transplant)- Forecast To 2022
Pune, India -- (SBWIRE) -- 03/05/2018 -- Global Bipolar Disorders and Treatment Market has been segmented on the basis of drug type which comprises of antidepressant drugs, anti-anxiety drugs, mood stabilizers, anticonvulsants and atypical antipsychotics. The Bipolar Disorders and Treatment Market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Global Bipolar Disorders and Treatment Market - Regional Analysis
North America dominates the global bipolar disorder and treatment market owing to increased awareness about bipolar disorder in the region and presence of major market players. The U.S. represents the largest market for bipolar disorder followed by Canada in North America region.
According to the National Institute of Mental Health (NIMH), bipolar disorder affects more than 5.7 million adults (about 3 % of the population) in the United States each year. The typical age is the late teens or early 20s, and a history of depression is common in people diagnosed with bipolar.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1566 .
Bipolar Disorders and Treatment Industry Segments:
Global bipolar disorders and treatment market has been segmented on the basis of drug type which comprises of antidepressant drugs, anti-anxiety drugs, mood stabilizers, anticonvulsants and atypical antipsychotics. On the basis of treatment include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and others.
Global Bipolar Disorders and Treatment Market - Competitive Analysis
AstraZeneca (U.K), Bristol-Myers Squibb (U.S), Eli Lilly and Company (U.S), GlaxoSmithKline PLC (U.K), Allergan (U.S), Janssen Pharmaceuticals (Belgium), Dainippon Sumitomo Pharma Co., Ltd (Japan), Lundbeck (Denmark), Abbott (U.S.), Cephalon Inc. (Teva Phamaceuticals), Dainippon Sumitomo Pharma Co. Ltd., Forest Laboratories Inc. (U.S.), Gedeon Richter PLC (Hungary), Otsuka America Pharmaceutical Inc., (U.S.) Repligen Corporation, (U.S.) and Pfizer Inc. (U.S.) are some of the prominent players at the forefront of competition in the Global Bipolar Disorders and Treatment Market and are profiled in MRFR Analysis.
The Global Bipolar Disorders and Treatment Market is growing with the rapid pace; mainly due to the increasing stress in life. According to a recent study report published by the Market Research Future, The global bipolar disorders and treatment market is booming and expected to gain prominence over the forecast period growing rapidly. On the basis of treatment include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and others. The Bipolar Disorders and Treatment Market report provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
Major TOC Bipolar Disorders and Treatment Industry:
1 Report Prologue
2 Market Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
Ask to Expertise @ https://www.marketresearchfuture.com/enquiry/1566 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.